Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
NCT00332956
Completed
This Phase 2(a) clinical trial is designed as a dose-blinded, block-randomized, multi-center study to select a dosage and schedule of rF1V vaccine for further studies based on the immune response up to Day 210. Additional immunogenicity and safety/reactogenicity data will be collected through Day 540. Selection of dosage and schedule will be based on GMCs and seroconversion rates for anti-F1, anti-V and anti-rF1V antibody titers. Approximately 400 healthy adult volunteers will be enrolled (100 p... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Alta Clinical Research, LLC, Tucson, Arizona +8 locations
Conditions: Healthy Volunteers
Register for Updates
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
NCT00764634
Completed
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Miami Research Associates, Miami, Florida +5 locations
Conditions: Botulism Vaccine
Register for Updates
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
NCT00391391
Completed
Primary Objective: To evaluate for each influenza strain the non-inferiority of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years. Secondary Objectives: * To describe the immunogenicity of of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years. * To describe the safety of of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subje... Read More
Gender:
ALL
Ages:
Between 6 months and 8 years
Trial Updated:
11/21/2011
Locations: Not set, Harrisburg, Arkansas +18 locations
Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Register for Updates
Pentavalent DTaP-Hep B-IPV
NCT00133445
Completed
The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration of a HepB vaccine at birth and the same combination vaccine at 2, 4, and 6 months of age. Additionally, researchers will assess the body's antibody response (proteins produced by the body's immune system that help fight infections) following each vaccine dose. The study will enroll 5 healthy newborns, ages 0-5 day... Read More
Gender:
ALL
Ages:
5 days and below
Trial Updated:
11/03/2011
Locations: UCLA Center For Vaccine Research, Torrance, California
Conditions: Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Register for Updates
Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA
NCT01033409
Completed
In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi (RASV) strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live biological vaccine vectors to evaluate safe and tolerable, single, oral dose levels in adult subjects.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
11/01/2011
Locations: Saint Louis University Center for Vaccine Development, St. Louis, Missouri
Conditions: Pneumonia
Register for Updates
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
NCT00824850
Completed
The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the... Read More
Gender:
ALL
Ages:
Between 8 years and 16 years
Trial Updated:
10/05/2011
Locations: Pfizer Investigational Site, Hayward, California +1 locations
Conditions: Pneumococcal Conjugate Vaccine
Register for Updates
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
NCT00002748
Completed
RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
10/03/2011
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
NCT00952276
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after a single injection. * To describe the safety of the candidate vaccines after a single injection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2011
Locations: Not set, Anaheim, California +14 locations
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Register for Updates
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
NCT00355121
Completed
The purpose of this study is to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and DAPTACEL® vaccine. The main objectives are: Immunogenicity: To evaluate the antibody responses to both vaccines when Menactra vaccine is given concomitantly with DAPTACEL® compared to when either vaccine is given alone. Safety: To evaluate the rate of local and systemic reactions when DAPTACEL® and Menactra vaccines are administered concomitantly compared to when... Read More
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
08/22/2011
Locations: Not set, Little Rock, Arkansas +25 locations
Conditions: Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Register for Updates
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
NCT00574548
Completed
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
Gender:
ALL
Ages:
Between 60 years and 64 years
Trial Updated:
07/18/2011
Locations: Pfizer Investigational Site, Chandler, Arizona +5 locations
Conditions: Pneumococcal Vaccines
Register for Updates
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
NCT00094653
Completed
The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an obje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2011
Locations: Arizona Cancer Center, Tucson, Arizona +208 locations
Conditions: Melanoma, Metastases
Register for Updates
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
NCT00861107
Completed
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant. In this study, tumor antigen is generated by freezing a tumor by a minimally invasive percutaneous (through the skin) cryoablation procedure. The study drug, AlloStim, is injected into the ablated tumor to promote development of an anti-tumor immune response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2011
Locations: Immunovative Clinical Research, Inc, Carlsbad, California
Conditions: Metastatic Cancer
Register for Updates